Maintaining Hold on IGM Biosciences: Assessing Acquisition Impact and Awaiting Clinical Data
IGM Biosciences Analyst Ratings
IGM Biosciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), IGM Biosciences (IGMS) and Elanco Animal Health (ELAN)
Stifel Nicolaus Sticks to Its Buy Rating for IGM Biosciences (IGMS)
Analysts' Opinions Are Mixed on These Healthcare Stocks: IGM Biosciences (IGMS) and Argenx Se (ARGX)
IGM Biosciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Alpine Immune Sciences (ALPN) and IGM Biosciences (IGMS)
IGM Biosciences Analyst Ratings
IGM Biosciences: A Balanced Hold Rating Amid Financial Stability and Drug Development Risks
IGM Biosciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Joint (JYNT), IGM Biosciences (IGMS) and Optinose (OPTN)
Analysts' Top Healthcare Picks: Inventiva (IVA), IGM Biosciences (IGMS)
RBC Capital Sticks to Their Buy Rating for IGM Biosciences (IGMS)
IGM Biosciences Analyst Ratings
IGM Biosciences Shares Upgraded to Outperform on $1B+ Long-term Opportunity
RBC Upgrades IGM Biosciences to Outperform From Sector Perform, Boosts Price Target to $21 From $9; Speculative Risk Kept
B of A Securities Downgrades IGM Biosciences to Neutral, Announces $8 Price Target
IGM Biosciences Analyst Ratings
HC Wainwright & Co. Downgrades IGM Biosciences to Neutral, Lowers Price Target to $7
No Data